- Home
- TFIN vs DVAX Comparison
TFIN vs DVAX Comparison
Compare TFIN & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TFIN
- DVAX
- Stock Information
- Founded
- TFIN 1981
- DVAX 1996
- Country
- TFIN United States
- DVAX United States
- Employees
- TFIN N/A
- DVAX N/A
- Industry
- TFIN Major Banks
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- TFIN Finance
- DVAX Health Care
- Exchange
- TFIN Nasdaq
- DVAX Nasdaq
- Market Cap
- TFIN 1.2B
- DVAX 1.2B
- IPO Year
- TFIN N/A
- DVAX 2004
- Fundamental
- Price
- TFIN $54.43
- DVAX $10.12
- Analyst Decision
- TFIN Buy
- DVAX Buy
- Analyst Count
- TFIN 4
- DVAX 4
- Target Price
- TFIN $62.00
- DVAX $26.50
- AVG Volume (30 Days)
- TFIN 280.2K
- DVAX 1.3M
- Earning Date
- TFIN 10-15-2025
- DVAX 11-05-2025
- Dividend Yield
- TFIN N/A
- DVAX N/A
- EPS Growth
- TFIN N/A
- DVAX N/A
- EPS
- TFIN 0.28
- DVAX N/A
- Revenue
- TFIN $412,291,000.00
- DVAX $316,268,000.00
- Revenue This Year
- TFIN $10.80
- DVAX $23.23
- Revenue Next Year
- TFIN $11.33
- DVAX $16.57
- P/E Ratio
- TFIN $194.74
- DVAX N/A
- Revenue Growth
- TFIN 3.78
- DVAX 26.66
- 52 Week Low
- TFIN $42.90
- DVAX $9.20
- 52 Week High
- TFIN $110.58
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- TFIN 49.57
- DVAX 50.46
- Support Level
- TFIN $53.03
- DVAX $10.11
- Resistance Level
- TFIN $61.26
- DVAX $10.58
- Average True Range (ATR)
- TFIN 2.91
- DVAX 0.24
- MACD
- TFIN 0.07
- DVAX 0.02
- Stochastic Oscillator
- TFIN 54.67
- DVAX 53.98
About TFIN Triumph Financial Inc.
Triumph Financial Inc is a financial holding company. The company has four reportable segments namely Banking, Factoring, Payments, and Intelligence. The Banking segment includes the operations of TBK Bank. The Factoring segment includes the operations of Triumph Financial Services with revenue derived from factoring services, The Payments segment includes the operations of TBK Bank's TriumphPay division which provides a presentment, audit and payment solution to Shipper, Broker, and Factor clients in the trucking industry and The Intelligence segment includes to turn the over-the-road trucking data collected through the services into actionable insights for their customers.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.